Cardiac optogenetics: a novel approach to cardiovascular disease therapy

Personalised care is integral to the delivery of the NHS England Long Term Plan. Enabling choice and supporting patients to make decisions predicated on ‘what matters to them’, rather than ‘what is the matter with them’ is a fundamental part of the NHS vision. Social prescribing uses non-medical, asset-based, salutogenic approaches to promote this personalised paradigm, and places the patient central to decision making. This article discusses how personalised care can be used to help people with cardiovascular disease using socially prescribed ‘nature-based’ interventions to support the pre-habilitation and rehabilitation of patients with cardiovascular disease. The concept of personalised care outlined and the significance of salutogenic principles as a complementary approach to the pathogenic model is discussed. The authors argue that this seemingly novel approach to using nature-based interventions can help promote wellbeing for people with cardiovascular disease as part of the wider personalised agenda.

Download Full-text

A novel approach to educate hospitalized cardiovascular disease patients about lifestyle and behavior modifications

BMC Medical Informatics and Decision Making ◽

10.1186/s12911-021-01680-x ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Atiyeh Saboktakin ◽

Mohammad Mehdi Sepehri ◽

Roghaye Khasha

Keyword(s):

Cardiovascular Disease ◽

Multiple Criteria Decision Making ◽

Training System ◽

Nursing Workload ◽

Structured Interviews ◽

Process Maps ◽

Risk Of Death ◽

Novel Approach ◽

Cardiovascular Patients ◽

And Behavior

Abstract Background Cardiovascular diseases (CVDs) are always considered by healthcare specialists for different reasons, including extensive prevalence, increased costs, chronicity, and high risk of death. The control of CVDs is highly influenced by behavior and lifestyle and it seems necessary to train special abilities about lifestyle and behavior modification to improve self-care skills for patients, and their caregivers. As a result, the development of effective training systems should be considered by healthcare specialists. Methods Hence, in this study, a framework for improving cardiovascular patients’ education processes is presented. Initially, an existing training system for cardiovascular patients is reviewed. Using field observations and targeted interviews with hospital experts, all components of its educating processes are identified, and their process maps are drawn up. After that, challenges in the training system are extracted with the aid of in-depth semi-structured interviews with experts. Due to the importance and different influence of the identified challenges, they are prioritized using a Multiple Criteria Decision-making (MCDM) method, and then their root causes were investigated. Finally, a novel framework is proposed and evaluated with hospital experts' help to improve the main challenges. Results The most important challenges included high nursing workload and shortage of time, lack of understanding of training concepts by patients, lack of attention to training, disruption of the training processes by the patients’ caregivers, and patient's weakness in understanding the standard language. In identifying the root causes, learner, educator, and educational tools are the most effective in the training process; therefore, the improvement scenarios were designed accordingly in the proposed framework. Conclusions Our study indicated that presenting a framework with applying different quantitative and qualitative methods has great potential to improve the processes of patient education for chronic diseases such as cardiovascular disease.

Download Full-text

Prenatal hypoxia and placental oxidative stress: linkages to developmental origins of cardiovascular disease

AJP Regulatory Integrative and Comparative Physiology ◽

10.1152/ajpregu.00245.2017 ◽

2017 ◽

Vol 313 (4) ◽

pp. R395-R399 ◽

Cited By ~ 28

Author(s):

Mais M. Aljunaidy ◽

Jude S. Morton ◽

Christy-Lynn M. Cooke ◽

Sandra T. Davidge

Keyword(s):

Oxidative Stress ◽

Cardiovascular Disease ◽

Intrauterine Growth Restriction ◽

Pregnancy Complication ◽

Growth Potential ◽

Developmental Origins ◽

Intrauterine Growth ◽

Novel Approach ◽

Placental Oxidative Stress ◽

Target Effects

Intrauterine growth restriction (IUGR, a pregnancy complication where the fetus does not reach its genetic growth potential) is a leading cause of fetal morbidity and mortality with a significant impact on population health. IUGR is associated with gestational hypoxia; which can lead to placental oxidative stress and fetal programming of cardiovascular disease. Mitochondria are a major source of placental oxidative stress and may provide a therapeutic target to mitigate the detrimental effects of placental oxidative stress on pregnancy outcomes. A nanoparticle-mediated delivery of a mitochondrial antioxidant to the placenta is a potential novel approach that may avoid unwanted off-target effects on the developing offspring.

Download Full-text

Tetrahydrobiopterin Improves Endothelial Function in Cardiovascular Disease: A Systematic Review

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2014/850312 ◽

2014 ◽

Vol 2014 ◽

pp. 1-7 ◽

Cited By ~ 11

Author(s):

Qiongying Wang ◽

Mina Yang ◽

Han Xu ◽

Jing Yu

Keyword(s):

Nitric Oxide ◽

Cardiovascular Disease ◽

Endothelial Dysfunction ◽

Early Stage ◽

Vascular Diseases ◽

Positive Outcome ◽

High Dose ◽

Cochrane Central Register ◽

Diabetic Vasculopathy ◽

Novel Approach

Background. Tetrahydrobiopterin (BH4) is a cofactor of nitric oxide synthase (NOS). Nitric oxide (NO) bioavailability is reduced during the early stage of vascular diseases, such as coronary artery disease, hypercholesterolemia, hypertension, and diabetic vasculopathy, and even throughout the entire progression of atherosclerosis.Methods. A literature search was performed using electronic databases (up to January 31, 2014), including MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), using an established strategy.Results. Fourteen articles were selected with a total of 370 patients. Ten of the fourteen studies showed a significant improvement in the endothelial dysfunction of various cardiovascular disease groups with BH4supplementation compared with the control groups or placebos. Three studies showed no positive outcome, and one study showed that low-dose BH4had no effect but that high-dose BH4did have a significantly different result.Conclusions. This review concludes that supplementation with BH4and/or augmentation of the endogenous levels of BH4will be a novel approach to improve the endothelial dysfunction observed in various cardiovascular diseases. BH4might be considered to be a new therapeutic agent to prevent the initiation and progression of cardiovascular disease.

Download Full-text

Heme Oxygenase-1 Upregulation: A Novel Approach in the Treatment of Cardiovascular Disease

Antioxidants and Redox Signaling ◽

10.1089/ars.2019.7970 ◽

2020 ◽

Vol 32 (14) ◽

pp. 1045-1060 ◽

Cited By ~ 3

Author(s):

Lars Bellner ◽

Nachum B. Lebovics ◽

Rochelle Rubinstein ◽

Yosef D. Buchen ◽

Emilia Sinatra ◽

...

Keyword(s):

Cardiovascular Disease ◽

Heme Oxygenase ◽

Heme Oxygenase 1 ◽

Novel Approach

Download Full-text

Article Commentary: Serum C-Reactive Protein (CRP), Target for Therapy or Trouble?

Biomarker Insights ◽

10.1177/117727190600100020 ◽

2006 ◽

Vol 1 ◽

pp. 117727190600100 ◽

Cited By ~ 2

Author(s):

Virginia B. Kraus ◽

Joanne M. Jordan

Keyword(s):

Cardiovascular Disease ◽

High Sensitivity ◽

Female Gender ◽

C Reactive Protein ◽

Cardiac Damage ◽

Reactive Protein ◽

Therapeutic Benefits ◽

Cardiovascular Side Effects ◽

Disease Therapy ◽

Hs Crp

High sensitivity serum C-reactive protein (hs-CRP) has come into clinical use as a marker of risk for cardiovascular disease (CVD). In addition to a role as a marker of disease, CRP has also been implicated in the pathogenesis of CVD. Specific small-molecule inhibitors of CRP have recently been developed with the intent of mitigating cardiac damage during acute myocardial infarction. However, the use of CRP, both as a risk marker and a disease target are controversial for several reasons. Serum hs-CRP concentrations can be elevated on the basis of genetics, female gender, and non-Caucasian ethnicity. It is not clear, in these contexts, that elevations of hs-CRP have any pathological significance. As a non-specific indicator of inflammation, CRP is also not a specific indicator of a single disease state such as cardiovascular disease but elevated concentrations can be seen in association with other comorbidities including obesity and pulmonary disease. In sharp contrast to the proposed inhibition of CRP for cardiovascular disease treatment, the infusion of CRP has been shown to have profound therapeutic benefits for autoimmune disease and septic shock. The balance between the risks and benefits of these competing views of the role of CRP in disease and disease therapy is reminiscent of the ongoing controversy regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal disease and their cardiovascular side effects. Soon, NSAIDs may not be the only agents about which Rheumatologists and Cardiologists may spar.

Download Full-text